Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms Clinical Trial

Official title:

A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3΄-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01411410
• Other study ID #: 12874
• Status: Completed
• Phase: Phase 1
• First received: August 5, 2011
• Last updated: October 10, 2017
• Start date: August 24, 2011
• Est. completion date: June 29, 2015

Study information

• Verified date: October 2017
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open label Phase 1 study involves treating subjects with advanced cancer with BAY80-6946 in combination with paclitaxel. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of BAY80-6946 in combination with paclitaxel. The trial will involve multiple participating sites from the US. Following determination of the MTD, an expansion cohort of 20 evaluable subjects with breast cancer was planned. Finally, 16 patients have been enrolled to treatment (Cohort 3). A new expansion cohort with modified dosing cohort is now introduced (Cohort 4: breast cancer expansion cohort with modified dosing) in which another 20 subjects are planned to be enrolled to treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: June 29, 2015
• Est. primary completion date: October 22, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have defined tumor classification (ie, TNBC, HER2+ or Luminal) for enrollment. If tumor classification is not available the subject cannot be enrolled. Tumor classification can be based on analysis of archived tumor tissue, or analysis of tumor tissue collected at any time proximal to screening. Subject profile can also be derived from analysis of fresh tumor tissue obtained during screening. Shipment of specimens (archival or fresh tumor tissue, blood, and plasma) to a central lab can take place after subject enrollment.

• No prior paclitaxel treatment for subjects in the dose escalation phase. MTD cohort expansion subjects may have had prior paclitaxel, but must not have experienced moderate or severe hypersensitivity reactions to the drug. Peripheral neuropathy must be Grade = 1.

• Histological or cytological documentation of non-hematologic malignant solid tumor, excluding primary brain or spinal tumors. Patients with prior central nervous system metastases are eligible if all of the following apply: -- Definitive treatment for all lesions (eg, surgery, radiation) was completed at least three months prior to enrollment -- All lesions must be stable or improving on MRI scan performed within one month of enrollment -- All symptoms of the prior CNS metastases are stable.

• At least one measurable lesion or evaluable disease, as per RECIST 1.1

• ECOG Performance Status Assessment of 0 or 1

• Life expectancy of at least 12 weeks

Exclusion Criteria:- History of moderate to severe hypersensitivity (allergy) to drugs formulated in Cremophor® EL (polyoxyethylated castor oil), such as vitamin K, cyclosporin for injection concentrate and teniposide for injection concentrate

• Pre-existing interstitial lung disease and/or severe impaired pulmonary function

• History of cardiac disease; congestive heart failure (CHF) >NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina, or ventricular cardiac arrhythmias requiring anti-arrhythmic therapy

• Prior diagnosis of Type 1 or 2 diabetes mellitus, hyperglycemia (defined as consistent fasting blood or plasma glucose > 125 mg/dL) or HgBA1c = 7%

• Active clinically serious infections Grade = 2 (NCI-CTCAE version 4.0), including viral hepatitis

• Poorly controlled seizure disorder

• Poorly controlled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management

• Known human immunodeficiency virus (HIV) infection or chronic hepatitis C or B

• Subjects undergoing renal dialysis

• Known bleeding diathesis

• Pregnant or breast feeding women.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Paclitaxel
Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg) Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted.
• Copanlisib (BAY80-6946)
BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse event collection		Up to 3 years or longer if indicated
Primary	Maximum tolerated dose, measured by adverse event profile		Up to 3 years or longer if indicated
Primary	Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed)	Cmax: maximum drug concentration in plasma after single dose administration	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed)	Cmax/D: Cmax divided by total dose in [mg]	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed)	tmax: time to reach maximum drug concentration in plasma after single (first) dose	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed)	AUC(0-tlast): AUC from time 0 to the last data point above lower limit of quantification	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed)	AUC: area under the plasma concentration vs time curve from zero to infinity	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed)	AUC/D: AUC divided by total dose in [mg]	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed)		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed)	AUC(0-25): area under the plasma concentration vs time curve from zero to 25 h p.a.	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed)		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed)		Multiple time points up to 6 weeks
Primary	Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only)	AE,ur(0-25): amount of drug excreted via urine during the collection interval 0 - 25 h	Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel		Multiple time points up to 6 weeks
Primary	Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15		Multiple time points up to 6 weeks
Primary	Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15		Multiple time points up to 6 weeks
Secondary	Number of patients with mutational status		Up to 3 years or longer if indicated
Secondary	Tumor Response as measured by RECIST 1.1 criteria		Up to 3 years or longer if indicated

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer products.